Patents by Inventor Kimberly Stegmaier

Kimberly Stegmaier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS
    Publication number: 20240075099
    Abstract: Methods for assessing the efficacy of internally cross-linked p53 transactivation domain-based inhibitor peptides in the treatment of pediatric cancer and methods of using such peptides to treat pediatric cancer are provided.
    Type: Application
    Filed: May 11, 2023
    Publication date: March 7, 2024
    Inventors: Loren D. Walensky, Kimberly Stegmaier, Ann Morgan Cathcart, Björn Stolte
  • KINASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20220160702
    Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3? or GSK3?) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychiatric disorders, metabolic disorders, and cancer.
    Type: Application
    Filed: June 10, 2021
    Publication date: May 26, 2022
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Florence Fevrier Wagner, Jennifer Q. Pan, Sivaraman Dandapani, Andrew Germain, Edward Holson, Benito Munoz, Partha P. Nag, Michael C. Lewis, Stephen J. Haggarty, Joshua A. Bishop, Kimberly Stegmaier, Michel Weiwer, Versha Banerji
  • COMPOSITIONS AND METHODS FOR IDENTIFICATION ASSESSMENT, PREVENTION, AND TREATMENT OF EWING SARCOMA USING TP53 DEPENDENCY BIOMARKERS AND MODULATORS
    Publication number: 20210324478
    Abstract: The present invention is based, in part, on the identification of TP53 dependency biomarkers, including MDM2, MDM4, USP7, and Wip1/PPM1D, as well as modulators and methods of use thereof, for identifying, assessing, preventing, and treating Ewing sarcoma.
    Type: Application
    Filed: July 17, 2019
    Publication date: October 21, 2021
    Inventor: Kimberly Stegmaier
  • Kinase inhibitors and methods of use thereof
    Patent number: 11052080
    Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3? or GSK3?) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychiatric disorders, metabolic disorders, and cancer.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: July 6, 2021
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Florence Fevrier Wagner, Jennifer Q. Pan, Sivaraman Dandapani, Andrew Germain, Edward Holson, Benito Munoz, Partha P. Nag, Michael C. Lewis, Stephen J. Haggarty, Joshua A. Bishop, Kimberly Stegmaier, Michel Weiwer, Versha Banerji
  • KINASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20200061050
    Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3? or GSK3?) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychriatic disorders, metabolic disorders, and cancer.
    Type: Application
    Filed: November 21, 2018
    Publication date: February 27, 2020
    Inventors: Florence Fevrier Wagner, Jennifer Q. Pan, Sivaraman Dandapani, Andrew Germain, Edward Holson, Benito Munoz, Partha P. Nag, Michael C. Lewis, Stephen J. Haggarty, Joshua A. Bishop, Kimberly Stegmaier, Michel Weiwer, Versha Banerji
  • Folate-conjugated molecules for delivery of toxic small molecule inhibitors to cancer cells and methods of use
    Patent number: 10525139
    Abstract: The invention relates to novel derivatives of thapsigargin that are chemically modified with a group that targets a cell surface-expressed receptor, and pharmaceutical preparations thereof. The invention further relates to methods of treating diseases such as cancer using the compounds of the invention.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: January 7, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James Bradner, Kimberly Stegmaier, Jun Qi, Anthony Varca, Giovanni Roti
  • KINASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20190175584
    Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3? or GSK3?) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychriatic disorders, metabolic disorders, and cancer.
    Type: Application
    Filed: November 21, 2018
    Publication date: June 13, 2019
    Inventors: Florence Fevrier Wagner, Jennifer Q. Pan, Sivaraman Dandapani, Andrew Germain, Edward Holson, Benito Munoz, Partha P. Nag, Michael C. Lewis, Stephen J. Haggarty, Joshua A. Bishop, Kimberly Stegmaier, Michel Weiwer, Versha Banerji
  • COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS
    Publication number: 20190076504
    Abstract: Methods for assessing the efficacy of internally cross-linked p53 transactivation domain-based inhibitor peptides in the treatment of pediatric cancer and methods of using such peptides to treat pediatric cancer are provided.
    Type: Application
    Filed: March 23, 2017
    Publication date: March 14, 2019
    Inventors: Loren D. Walensky, Kimberly Stegmaier, Ann Maurine Morgan, Björn Stolte
  • Kinase inhibitors and methods of use thereof
    Patent number: 10137122
    Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3? or GSK3?) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychiatric disorders, metabolic disorders, and cancer.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: November 27, 2018
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Florence Fevrier Wagner, Jennifer Q. Pan, Sivaraman Dandapani, Andrew Germain, Edward Holson, Benito Munoz, Partha P. Nag, Michael C. Lewis, Stephen J. Haggarty, Joshua A. Bishop, Kimberly Stegmaier, Michel Weiwer, Versha Banerji
  • FOLATE-CONJUGATED MOLECULES FOR DELIVERY OF TOXIC SMALL MOLECULE INHIBITORS TO CANCER CELLS AND METHODS OF USE
    Publication number: 20180280522
    Abstract: The invention relates to novel derivatives of thapsigargin that are chemically modified with a group that targets a cell surface-expressed receptor, and pharmaceutical preparations thereof. The invention further relates to methods of treating diseases such as cancer using the compounds of the invention.
    Type: Application
    Filed: November 5, 2015
    Publication date: October 4, 2018
    Inventors: James Bradner, Kimberly Stegmaier, Jun Qi, Anthony Varca, Giovanni Roti
  • KINASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20150313890
    Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3? or GSK3?) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychiatric disorders, metabolic disorders, and cancer.
    Type: Application
    Filed: July 14, 2015
    Publication date: November 5, 2015
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Florence Fevrier Wagner, Jennifer Q. Pan, Sivaraman Dandapani, Andrew Germain, Edward Holson, Benito Munoz, Partha P. Nag, Michael C. Lewis, Stephen J. Haggarty, Joshua A. Bishop, Kimberly Stegmaier, Michel Weiwer, Versha Banerji
  • Kinase inhibitors and methods of use thereof
    Patent number: 9096594
    Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3? or GSK3?) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychiatric disorders, metabolic disorders, and cancer.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: August 4, 2015
    Assignees: The Broad Institute, Inc., The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Florence Fevrier Wagner, Jennifer Q. Pan, Sivaraman Dandapani, Andrew Germain, Edward Holson, Benito Munoz, Partha P. Nag, Michel Weiwer, Michael C. Lewis, Stephen J. Haggarty, Joshua A. Bishop, Kimberly Stegmaier, Versha Banerji
  • CELASTROL, GEDUNIN, AND DERIVATIVES THEREOF AS HSP90 INHIBITORS
    Publication number: 20110263693
    Abstract: Based on the discovery that celastrol and gedunin are Hsp90 inhibitors, the present invention provides novel inhibitors of Hsp90. and pharmaceutically acceptable salts, derivatives, and compositions thereof. The invention provides two classes of compounds. One class includes celastrol and its derivatives. The other class includes gedunin and its derivatives. The present invention further provides methods for treating disorders wherein Hs?90 inhibition is desired (e.g., proliferative diseases, cancer, inflammatory diseases, fungal infections, etc.) comprising administering a therapeutically effective amount of an inventive compound to a subject in need thereof. Celastrol, gedunin, and derivatives thereof are particularly useful in the treatment of prostate cancer, breast cancer, ovarian cancer, lung cancer, and leukemia.
    Type: Application
    Filed: March 30, 2007
    Publication date: October 27, 2011
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Haley Vinson-Hieronymus, Todd R. Golub, Justin Lamb, Kimberly Stegmaier